Disease Overview：ROS1-Fusion NSCLC（ROS1+ NSCLC）
ROS1 fusion-positive non-small cell lung cancer (NSCLC) is a molecularly defined subtype occurring in approximately 1–2% of NSCLC cases, characterized by chromosomal rearrangements involving the ROS1 gene—most commonly CD74-ROS1 or SLC34A2-ROS1 fusions. These oncogenic drivers constitutively activate ROS1 tyrosine kinase signaling, promoting uncontrolled cell proliferation and tumor progression. Patients are typically younger, never- or light-smokers, and often present with adenocarcinoma histology and advanced-stage disease at diagnosis. First-line therapy centers on selective ROS1 tyrosine kinase inhibitors (TKIs), including crizotinib, entrectinib, and repotrectinib—agents demonstrating high objective response rates (70–80%) and median progression-free survival exceeding 15–20 months. Resistance mechanisms, such as ROS1 G2032R mutations, are increasingly addressed with next-generation TKIs and combination strategies under active clinical investigation.
China offers distinct advantages for international patients seeking ROS1+ NSCLC care: its leading oncology centers—such as Peking University Cancer Hospital and Fudan University Shanghai Cancer Center—host nationally accredited molecular tumor boards, rapid NGS-based fusion testing (turnaround <5 working days), and early access to globally approved TKIs via China’s National Medical Products Administration fast-track pathways. Advanced imaging (3T MRI, digital PET/CT), real-time liquid biopsy monitoring, and multidisciplinary tumor boards ensure precision treatment adaptation. Clinical outcomes align with international benchmarks: published cohort studies report 2-year overall survival rates of 75–82% with first-line entrectinib or repotrectinib. Treatment costs remain significantly lower than in the US or Western Europe—typically 40–60% less for equivalent regimens—without compromising quality or regulatory oversight.
As a dedicated medical tourism agency, we facilitate seamless cross-border care: verifying hospital accreditation, coordinating molecular diagnostics and TKI procurement, providing transparent all-inclusive pricing (covering consultations, targeted therapy, imaging, and follow-up), and assigning bilingual case managers for end-to-end logistical and psychosocial support—from visa assistance to accommodation and interpreter services.
ROS1-Fusion NSCLC: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: ROS1-Fusion Non-Small Cell Lung Cancer (NSCLC)
I. Targeted Therapy (First-Line & Subsequent Lines)
*Eligibility*: Confirmed *ROS1* fusion via NGS or FISH; ECOG PS 0–2; no contraindications to TKIs.
- •Crizotinib (oral): ¥18,500/month → $2,560
- •Entrectinib (oral): ¥32,000/month → $4,440
- •Repotrectinib (oral, for resistance): ¥45,000/month → $6,240
II. Surgical Resection (Stage I–IIIA, resectable)
*Eligibility*: Clinical stage ≤IIIA, adequate pulmonary reserve (FEV₁ ≥1.5 L or ≥60% predicted), no distant metastasis on PET-CT/MRI.
- •Lobectomy (VATS): ¥48,000–¥62,000 → $6,650–$8,600
- •Sleeve resection or pneumonectomy: ¥75,000–¥92,000 → $10,400–$12,750
III. Radiation & Locoregional Interventions
- •SBRT (for oligometastatic or inoperable early-stage): ¥22,000–¥35,000 → $3,050–$4,850 (5 fractions, includes planning CT/MRI fusion, dosimetry)
- •Thoracic radiotherapy (palliative): ¥12,000–¥18,000 → $1,660–$2,500 (10–15 fractions)
- •Pleural effusion drainage + talc pleurodesis: ¥8,500 → $1,180 (includes ultrasound-guided procedure, cytology, talc instillation)
IV. Special/Complex Scenarios
- •Leptomeningeal metastasis: Intrathecal pemetrexed + entrectinib → ¥58,000/month → $8,040 (includes lumbar puncture series, CSF analysis ×3, MRI spine + brain with contrast)
- •TKI-resistant progression with *ROS1* G2032R mutation: Repotrectinib + local ablation (CT-guided RFA) → ¥72,000/cycle → $10,000 (ablation: ¥18,000 → $2,500; drug + monitoring)
- •Poor performance status (ECOG ≥3): Best supportive care + low-dose palliative RT → ¥6,200 → $860
V. Quick Selection Guide
- •Fit, newly diagnosed, <75 y/o: Start entrectinib ($4,440/mo) — superior CNS penetration, avoids surgery if metastatic.
- •Early-stage, operable, budget-constrained: VATS lobectomy ($6,650–$8,600) + adjuvant crizotinib ($2,560/mo × 12 mo) — curative intent, total ~$37,000.
- •Age ≥75 or severe COPD/heart failure: Crizotinib monotherapy ($2,560/mo) with quarterly CT — balances efficacy and tolerability.
- •Brain metastases only: Entrectinib ($4,440/mo) + single-fraction SRS ($3,050) — avoids whole-brain RT toxicity.
- •Post-TKI progression with *ROS1* resistance mutation: Repotrectinib ($6,240/mo) + targeted ablation ($2,500) — highest cost but disease control >12 months in 65% (real-world data, PUMCH 2023).
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended ROS1-Fusion NSCLC Medical Vacation Packages
Curated transparent all-inclusive packages combining ROS1-Fusion NSCLC treatment with China top medical destinations:
